medigraphic.com
ISSN 1028-4818 (Electronic)

2020, Number 4

<< Back Next >>

Mul Med 2020; 24 (4)

Clinical, biochemical and metabolic parameters predictive of micro and macrovascular complications in type 2 diabetics

Sarduy RA, Cruz ME, Milanés OMR, Mompié GGR

Language: Spanish
References: 25
Page: 836-852
PDF size: 402.26 Kb.


ABSTRACT

Introduction: diabetes mellitus (DM) is an endocrine-metabolic, vascular, chronic disease, produced by a variable interaction of genetic and environmental factors. Currently DM2 is considered by some authors as pandemic, without the existence of signs of reduction of incidence rates.
Objective: to identify clinical, biochemical and metabolic parameters predictors of micro and macrovascular complications in people with type 2 diabetes mellitus.
Method: an analytical case and control study was conducted with patients admitted to the Bayamo Diabetic Care Center (CAD), Granma, from 2010 to 2017, 81 with some microvascular complications, 40 with some macrovascular complications and 162 without any complications.
Results: the univariate analysis found that disease progression time and uncontrolled HTA were the risk factors for the development of a microvascular complication, while these were joined by smoking and hypercholesterolemia as risk factors for the development of macrovascular complications. The variables that showed an independent relationship with the risk of developing some microvascular complications were the time of disease evolution and uncontrolled HTA, while for the development of macrovascular complications were the time of disease evolution and smoking.
Conclusions: the time of evolution of diabetes and uncontrolled HTA and the time of disease and smoking evolution are independently associated with the emergence of microvascular and macrovasculate complications respectively.


REFERENCES

  1. Pompa Carrazana GS, Álvarez A, Almira A. Factores de riesgo para el desarrollo de complicaciones crónicas en pacientes diabéticos tipo 2. Convención Internacional de Salud, Cuba Salud 2018. [Internet]. 2018 [citado 14/10/2019]. Disponible en: http://www.convencionsalud2018.sld.cu/index.php/connvencionsalud/2018/paper/viewFile/797/300

  2. Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010; 123: s12-s18.

  3. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald CH, Lochnan HA, et al. Effects of intensive glycaemic contro on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014; 384(9958): 1936-41.

  4. Kassa Birarra M, Asmelashe Gelayee D. Metabolic syndrome among type 2 diabetic patients in Ethiopia: a cross-sectional study. BMC Cardiovasc Disord 2018; 18: 149.

  5. Fekadu Wolde H, Atsedeweyen A, Jember A, Awoke T, Mequanent M, Tesfahun Tsegaye A, Alemu S. Predictors of vascular complications among type 2 diabetes mellitus patients at University of Gondar Referral Hospital: a retrospective follow-up study. BMC Endocr Disord 2018; 18: 52.

  6. Toth P, Simko RJ, Rao Palli S, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012; 11: 109.

  7. Font Difour MV, del Valle García N, Sánchez Bonne AH, Gallego Galano J, Lashey Olivares ML. Caracterización de pacientes diabéticos de tipo II con complicaciones vasculares y riesgo de ateroesclerosis. MEDISAN 2014; 18(12): 1686-92.

  8. Agudelo M, Dávila CA. Burden of mortality due to diabetes mellitus in Latin America 2000-2011: the case of Argentina, Chile, Colombia, and Mexico. Gac Sanit [Internet] 2015 [citado 2019 enero 21]; 29 (3). Disponible en: http://fliphtml5.com/yadm/vxld/basic/

  9. International Diabetes Federation. The IDF Diabetes Atlas. 8va Ed. Brussels: International Diabetes Federation; 2017.

  10. MINSAP. Anuario Estadístico de Salud 2017. [Internet]. La Habana: OPS; 2018. [citado 21/1/2020]. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf

  11. Tracey Marsha L, McHugh Sheena M, Fitzgerald Anthony P, Buckley Claire M, Canavan Ronan J, Kearney Patricia M. Risk Factors for Macro- and Microvascular Complications among Older Adults with Diagnosed Type 2 Diabetes: Findings from The Irish Longitudinal Study on Ageing. Journal of Diabetes Research 2016; 2016: 1-9.

  12. Céspedes Miranda EM, Riverón Forment G, Alonso Rodríguez C, Cabrera Pérez-Sanz E. Control glucémico y daño oxidativo a biomoléculas en diabéticos tipo 2. Rev Cubana Endocrinol 2014; 25(2): 46-56.

  13. American Diabetes Association. Standards of Medical Care in Diabetes-2013. Classification and diagnosis. Diabetes Care 2013; 36(suppl 1): S11.

  14. Expert Panel, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary on Detection of the Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Treatment Panel III). Adult JAMA 2001; 285: 2486-97.

  15. Alaboud AF, Tourkmani AM, Pharm D, Alharbi TJ, Alobikan AH, Abdelhay O, et al. Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia. Saudi Med J 2016; 37(12): 1408–1411.

  16. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: ¿Distinct or continuum? Indian J Endocrinol Metabol 2016; 20(4): 546–551.

  17. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database of Syst Rev 2015; 1: CD006127.

  18. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313: 603–615.

  19. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4):527-32.

  20. Papa G, Degano C, Lurato MP, Licciardello C, Maiorana R, Finocchiaro C. Macrovascular Complication Phenotypes in Type 2 Diabetic Patients Cardiovasc Diabetol [Internet]. 2013 [citado 10/3/2019]; 12(20). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558439/

  21. Rana JS, Liu JY, Mofet HH, Jafe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Internal Med 2016;3 1(4): 387-93.

  22. Valdés Ramos ER, Espinosa Benítez Y. Factores de riesgo asociados con la aparición de enfermedad arterial periférica en personas con diabetes mellitus tipo 2. Revista Cubana de Medicina 2013; 52(1): 4-13.

  23. Stone GW, Maehara A, Lansky AJ, De BB, Cristea E, Mintz GS, et-al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-35.

  24. Śliwińska-Mossoń M, Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diabetes & Vascular Disease Research 2017; 14(4): 265–276.

  25. Valdés Ramos E, Bencosme Rodríguez N. Las complicaciones macrovasculares y su relación con algunas variables clínicas y bioquímicas en diabéticos tipo 2. Rev Cubana Endocrinol 2010; 21(3): 256-268.




2020     |     www.medigraphic.com